Illumina (NASDAQ:ILMN) Shares Gap Up to $194.01

Illumina, Inc. (NASDAQ:ILMN – Get Rating) gapped up prior to trading on Monday . The stock had previously closed at $194.01, but opened at $213.07. Illumina shares last traded at $222.45, with a volume of 842,478 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. StockNews.com cut shares of Illumina from a “hold” rating to a “sell” rating in a research report on Wednesday, February 8th. SVB Leerink lifted their price objective on shares of Illumina from $249.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 8th. Canaccord Genuity Group reduced their price target on shares of Illumina from $330.00 to $300.00 and set a “buy” rating for the company in a research report on Tuesday, January 17th. Citigroup lowered shares of Illumina from a “neutral” rating to a “sell” rating and reduced their price target for the company from $200.00 to $180.00 in a research report on Monday, December 12th. Finally, OTR Global raised shares of Illumina from a “mixed” rating to a “positive” rating in a report on Tuesday, December 20th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $249.55.

Illumina Price Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 1.28 and a quick ratio of 1.08. The firm has a market capitalization of $35.69 billion, a P/E ratio of -8.07, a P/E/G ratio of 7.07 and a beta of 1.15. The firm’s 50 day simple moving average is $207.42 and its two-hundred day simple moving average is $208.35.

Illumina (NASDAQ:ILMN – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.11). The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a negative net margin of 96.12% and a positive return on equity of 3.79%. The business’s revenue was down 9.2% on a year-over-year basis. During the same period last year, the company posted $0.75 earnings per share. As a group, analysts predict that Illumina, Inc. will post 1.41 earnings per share for the current year.

Insider Activity

In other news, SVP Aimee L. Hoyt sold 871 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $205.57, for a total transaction of $179,051.47. Following the completion of the transaction, the senior vice president now directly owns 2,796 shares of the company’s stock, valued at $574,773.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, SVP Aimee L. Hoyt sold 871 shares of the business’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $205.57, for a total transaction of $179,051.47. Following the transaction, the senior vice president now owns 2,796 shares in the company, valued at $574,773.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction dated Friday, January 6th. The shares were sold at an average price of $204.58, for a total transaction of $102,290.00. Following the transaction, the senior vice president now owns 38,662 shares in the company, valued at approximately $7,909,471.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,186 shares of company stock valued at $2,255,837. Insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Illumina

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Illumina by 1.4% in the third quarter. Vanguard Group Inc. now owns 12,836,349 shares of the life sciences company’s stock worth $2,449,047,000 after purchasing an additional 181,628 shares during the period. Polen Capital Management LLC grew its holdings in Illumina by 11.7% in the fourth quarter. Polen Capital Management LLC now owns 5,048,402 shares of the life sciences company’s stock worth $1,020,787,000 after purchasing an additional 527,005 shares during the period. Alliancebernstein L.P. grew its holdings in Illumina by 145.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,869,403 shares of the life sciences company’s stock worth $782,393,000 after purchasing an additional 2,294,942 shares during the period. Geode Capital Management LLC grew its holdings in Illumina by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,873,375 shares of the life sciences company’s stock worth $579,813,000 after purchasing an additional 58,652 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Illumina by 268.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,113,230 shares of the life sciences company’s stock worth $427,295,000 after purchasing an additional 1,539,186 shares during the period. Hedge funds and other institutional investors own 87.97% of the company’s stock.

About Illumina

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.